198 related articles for article (PubMed ID: 16025321)
41. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
42. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Mabrouk OS; Marti M; Morari M
Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3,5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl]-1H-benzimidazole, with anxiolytic potential.
Hirao A; Imai A; Sugie Y; Tamura T; Shimokawa H; Toide K
Eur J Pharmacol; 2008 Jan; 579(1-3):189-95. PubMed ID: 18001707
[TBL] [Abstract][Full Text] [Related]
44. A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory.
Higgins GA; Kew JN; Richards JG; Takeshima H; Jenck F; Adam G; Wichmann J; Kemp JA; Grottick AJ
Eur J Neurosci; 2002 Mar; 15(5):911-22. PubMed ID: 11906533
[TBL] [Abstract][Full Text] [Related]
45. 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists.
Wichmann J; Adam G; Röver S; Cesura AM; Dautzenberg FM; Jenck F
Bioorg Med Chem Lett; 1999 Aug; 9(16):2343-8. PubMed ID: 10476866
[TBL] [Abstract][Full Text] [Related]
46. Nociceptin (ORL-1) and mu-opioid receptors mediate mitogen-activated protein kinase activation in CHO cells through a Gi-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization.
Hawes BE; Fried S; Yao X; Weig B; Graziano MP
J Neurochem; 1998 Sep; 71(3):1024-33. PubMed ID: 9721727
[TBL] [Abstract][Full Text] [Related]
47. Antitussive profile of the NOP agonist Ro-64-6198 in the guinea pig.
McLeod RL; Jia Y; Fernandez X; Parra LE; Wang X; Tulshian DB; Kiselgof EJ; Tan Z; Fawzi AB; Smith-Torhan A; Zhang H; Hey JA
Pharmacology; 2004 Jul; 71(3):143-9. PubMed ID: 15161996
[TBL] [Abstract][Full Text] [Related]
48. Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung.
Corboz MR; Rivelli MA; Egan RW; Tulshian D; Matasi J; Fawzi AB; Benbow L; Smith-Torhan A; Zhang H; Hey JA
Eur J Pharmacol; 2000 Aug; 402(1-2):171-9. PubMed ID: 10940371
[TBL] [Abstract][Full Text] [Related]
49. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles.
Varty GB; Grilli M; Forlani A; Fredduzzi S; Grzelak ME; Guthrie DH; Hodgson RA; Lu SX; Nicolussi E; Pond AJ; Parker EM; Hunter JC; Higgins GA; Reggiani A; Bertorelli R
Psychopharmacology (Berl); 2005 Apr; 179(1):207-17. PubMed ID: 15682298
[TBL] [Abstract][Full Text] [Related]
50. Involvement of the histaminergic system in the nociceptin-induced pain-related behaviors in the mouse spinal cord.
Sakurada S; Watanabe H; Mizoguchi H; Yonezawa A; Orito T; Katsuyama S; Kuramasu A; Sakurada C; Yanai K; Sakurada T
Pain; 2004 Nov; 112(1-2):171-82. PubMed ID: 15494198
[TBL] [Abstract][Full Text] [Related]
51. Biphasic regulation of the acute μ-withdrawal and CCk-8 contracture responses by the ORL-1 system in guinea pig ileum.
Marini P; Romanelli L; Valeri D; Cascio MG; Tucci P; Valeri P; Palmery M
Pharmacol Res; 2012 Jan; 65(1):100-10. PubMed ID: 21875667
[TBL] [Abstract][Full Text] [Related]
52. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
Nicolas LB; Kolb Y; Prinssen EP
Eur J Pharmacol; 2006 Oct; 547(1-3):106-15. PubMed ID: 16934246
[TBL] [Abstract][Full Text] [Related]
53. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801.
Yamada H; Nakamoto H; Suzuki Y; Ito T; Aisaka K
Br J Pharmacol; 2002 Jan; 135(2):323-32. PubMed ID: 11815367
[TBL] [Abstract][Full Text] [Related]
55. A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.
Smith ED; Ariane Vinson N; Zhong D; Berrang BD; Catanzaro JL; Thomas JB; Navarro HA; Gilmour BP; Deschamps J; Carroll FI
Bioorg Med Chem; 2008 Jan; 16(2):822-9. PubMed ID: 17976996
[TBL] [Abstract][Full Text] [Related]
56. Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference.
Kotlińska J; Wichmann J; Legowska A; Rolka K; Silberring J
Behav Pharmacol; 2002 May; 13(3):229-35. PubMed ID: 12122313
[TBL] [Abstract][Full Text] [Related]
57. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test.
Redrobe JP; Calo' G; Regoli D; Quirion R
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):164-7. PubMed ID: 11819035
[TBL] [Abstract][Full Text] [Related]
58. Nociceptin and the NOP receptor in aversive learning in mice.
Adem A; Madjid N; Kahl U; Holst S; Sadek B; Sandin J; Terenius L; Ögren SO
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1298-1307. PubMed ID: 29102248
[TBL] [Abstract][Full Text] [Related]
59. Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.
Yokoyama F; Yamauchi M; Oyama M; Okuma K; Onozawa K; Nagayama T; Shinei R; Ishikawa M; Sato Y; Kakui N
Psychopharmacology (Berl); 2009 Aug; 205(2):177-87. PubMed ID: 19357839
[TBL] [Abstract][Full Text] [Related]
60. Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety.
Podhorna J; Brown RE
Br J Pharmacol; 2000 Jun; 130(4):739-46. PubMed ID: 10864879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
